New Data Evaluating KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy for First-Line Treatment of Non-Small Cell Lung Cancer Demonstrate Response Rates Ranging from 48 to 71 Percent
Dateline City:
KENILWORTH, N.J.
Based on Initial Results Presented at 2016 ASCO Annual Meeting, Merck Has Initiated Two Phase 3 Studies
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced findings from an initial proof-of-concept study of
KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy,
combined with standard treatments, one with bevacizumab and others
without, in non-small cell lung cancer (NSCLC) including chemotherapy in
previously untreated patients with NSCLC; the study showed overall
response rates (ORR) ranging from 48 to 71 percent, depending on the
therapy used.
Language:
English
Contact:
MerckMedia Contacts:Pamela Eisele, (267) 305-3558orCourtney Ronaldo, (908) 236-1108orInvestor Contacts:Teri Loxam, (908) 740-1986orJustin Holko, (908) 740-1879
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more
Source: Merck.com - Research and Development News - Category: Pharmaceuticals Tags: Oncology Newsroom Research and Development News Corporate News Latest News #Merck #MRK $MRK Keytruda Lung Cancer MSD Source Type: news
More News: Avastin | Cancer | Cancer & Oncology | Chemotherapy | Lung Cancer | Merck | Non-Small Cell Lung Cancer | Pharmaceuticals | Study